News
-
-
PRESS RELEASE
Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Sartorius Stedim Biotech SA discloses transactions by persons discharging managerial responsibilities & closely associated persons. Details of recent transaction provided -
-
-
PRESS RELEASE
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share for fiscal 2023 at the Annual Shareholders’ Meeting, with total distributed profit of 67.1 million euros. Financial calendar and company profile included -
PRESS RELEASE
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights. The company aims to use the proceeds to accelerate debt deleveraging and strengthen strategic flexibility. Sartorius AG subscribed for approximately 400 million euros, representing approximately one-third of the Capital Increase -
PRESS RELEASE
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
Sartorius Stedim Biotech S.A. launches a 1.2 billion euro share offering without shareholders' preferential subscription rights through bookbuilding process to reduce debt and enhance strategic flexibility -
PRESS RELEASE
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA declares the total number of shares, theoretical voting rights, and net voting rights making up the issued capital, in accordance with regulatory requirements -
PRESS RELEASE
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook. The company expects sales revenue growth in the mid to high single-digit percentage range with an underlying profit margin of more than 30 percent. Keywords: Sartorius Stedim Biotech, preliminary results, fiscal 2023, 2024 guidance, midterm outlook. -
